Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Neurobiological Technologies, Inc. (OTC Markets: NTII) (NTI or the Company) announced today that its board of directors has declared an extraordinary dividend of $0.05 per share...
Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors PR Newswire NEW YORK, LONDON and...
Company also Announces Timing and Plans to Voluntarily Delist from the Nasdaq Capital Market and Initiate Dissolution Process EMERYVILLE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Neurobiological...
Board of Directors Declares Extraordinary Dividend of $0.75 per share EMERYVILLE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced...
EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced today it has submitted written notice to the NASDAQ Stock Market LLC...
EMERYVILLE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq...
EMERYVILLE, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. announced today that its financial statements for the fiscal year ended June 30, 2007, included in the...
Scimitar Equity Research Issues Q3/05 Review of Neurobiological Technologies, Inc. BOSTON, May 11 /PRNewswire-FirstCall/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of...
Scimitar Equity Research Issues Review of Neurobiological Technologies, Inc. BOSTON, Aug. 20 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issued a review of Neurobiological...
Conference Call Alert - Neurobiological Technologies, Inc. (Nasdaq: NTII) RICHMOND, Calif., April 21 /PRNewswire-FirstCall/ -- Please join us for an in-depth update regarding the initiation of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 6971 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 6971 | 1.0E-6 | CS |
| 26 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 2324 | 1.0E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 296107 | 9.553E-5 | CS |
| 156 | 0 | 0 | 1.0E-6 | 0.001 | 1.0E-6 | 132666 | 9.54E-5 | CS |
| 260 | -0.003999 | -99.975 | 0.004 | 0.03 | 1.0E-6 | 55858 | 0.00380457 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
